Syncona is a FTSE 250 healthcare company focused on creating global leaders in life sciences. We operate as a hands-on venture capital, working closely with world class scientists to found, build and scale companies with the aim of delivering transformational treatments to patients. We invest in all therapeutic modalities (e.g., small molecules, antibodies, nucleic acid therapies) and currently have 11 companies in our portfolio that are developing therapies to treat diseases such as cancer, neurological disorders, metabolic disorders and inherited retinal disorders. In parallel to supporting our portfolio companies, we are also constantly looking for the next breakthroughs in science and medicine and remain actively engaged with the academic and clinician communities.
During this internship, the individual will take part in Syncona’s full operating rhythm, attend internal meetings and be exposed to all new investment opportunities explored by the team. The individual will work closely with experienced members of the team to develop Syncona’s investment strategy in specific biological, technological and clinical areas of interest, as well as contribute to the diligence of active new opportunities. Examples of currently active opportunities include novel antibody-based therapies for auto-immune diseases, cell therapies for cancer and novel nucleic acid therapies for metabolic disorders.